Aditxt stock analysis
Aditxt (ADTX) Stock Price & Analysis
ADTX Stock Chart & Stats
- Day’s Range
- $0.02 - $0.06
- 52-Week Range
- $0.01 - $53,429.11
- Previous Close
- $0.02
- Volume
- N/A
- Average Volume (3M)
- 250.96M
- Market Cap
- $399.19K
- Enterprise Value
- $3.96T
- Total Cash (Recent Filing)
- $268.85K
- Total Debt (Recent Filing)
- $4.23M
- Price to Earnings (P/E)
- 0.0
- Beta
- 0.84
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Aditxt News
Ignite Proteomics launches prospective oncology registry up to 10,000 patients
Ignite Proteomics announced the launch of a prospective oncology registry enrolling up to 10,000 patients. The registry is designed to pair Ignite’s CLIA-certified Reverse Phase Protein Array platform with structured
ADTX FAQ
What was Aditxt’s price range in the past 12 months?
What is Aditxt’s market cap?
When is Aditxt’s upcoming earnings report date?
Is Aditxt overvalued?
Does Aditxt pay dividends?
What is Aditxt’s EPS estimate?
How many shares outstanding does Aditxt have?
Which hedge fund is a major shareholder of Aditxt?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aditxt
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeffrey Busch
- Employees
- 26
- Website
- www.aditxt.com
- Address
- 2569 Wyandotte Street, Mountain View, CA, 94043, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 13 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 3 | 0 | 9 |










